Loading market dashboard
Amgen Inc.
AMGNHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
This ETF's dividend yield was recently a solid 3.25%, about three times that of the S&P 500. Its growth rate has been better than that of many dividend-focused funds.
Explore the exciting world of Amgen (AMGN +1.15%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
Amgen Inc. is upgraded to a cautious Buy, reflecting improved fundamentals, a diversified pipeline, and a decent risk/reward profile despite recent underperformance versus the S&P. Key growth drivers include Imdelltra, Uplizna, Tepezza, Repatha, and the promising but unproven Maritide, offsetting declines from legacy drugs like Prolia. AMGN's robust R&D pipeline, margin expansion, and capital investments are positioning the company for sustained long-term growth, though high debt and capex warrant monitoring.
Amgen NASDAQ: AMGN executives used a Jefferies investor conference appearance to emphasize the company's first-quarter growth, its late-stage pipeline and its preparations for potential launches, including the obesity candidate MariTide.
THOUSAND OAKS, Calif., June 4, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 47th Annual Global Healthcare Conference at 9:20 a.m.
Amgen Inc. (AMGN) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Compare diversification strategies and see how each ETF's unique index focus shapes risk and return for healthcare sector investors.
/PRNewswire/ -- Компания Amgen (NASDAQ: AMGN) сегодня объявила, что Европейская комиссия (ЕК) выдала регистрационное удостоверение на препарат IMDYLLTRA
New Phase 3 MITIGATE Open-Label Extension Data Support the Long-Term Safety Profile and Sustained Results of UPLIZNA ® in IgG4-RD Real-World Evidence Supports TAVNEOS ® Efficacy and Safety Profile with Reduced Steroid Use in ANCA-Associated Vasculitis THOUSAND OAKS, Calif., June 3, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data across rare autoimmune and inflammatory diseases at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, taking place from June 3-6 in London.
AMGN wins EU approval for Imdylltra in extensive-stage small cell lung cancer after phase III data showed a 40% reduction in death risk.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
THOUSAND OAKS, Calif., May 29, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Jefferies Global Healthcare Conference at 9:55 a.m.
Most people think you can't time the market. That's nonsense.
NVO and AMGN square off as GLP-1 leadership, pipeline depth and diversification shape a compelling healthcare stock comparison.
LOS ANGELES, May 27, 2026 /PRNewswire/ -- Ember LifeSciences, Inc., ("Ember") a leading provider of revolutionary cold chain technology, today announced strategic investments from Amgen Ventures, the corporate venture arm of Amgen (NASDAQ: AMGN ) a leading global biotechnology company and TDF Ventures, a venture capital firm focused on early-stage investments in enterprise-focused technology sectors. The investments follow Ember LifeSciences' previously announced Series A financing led by Sea Court Capital and comes as the company announces full commercial availability of the Ember Cube 2, an award-winning, reusable, modular solution designed to bring greater control and visibility to cold chain logistics through real-time monitoring and cloud-based tracking.
On May 26, 1896, Charles Dow calculated a simple arithmetic average of 12 industrial stocks and arrived at a closing value of 40.94. Now, exactly 130 years later, that same benchmark has crossed the historic 50,000 threshold.
Amgen faces LOE headwinds and pricing pressure, yet key growth drugs and biosimilars continue gaining traction.
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Amgen delivers consistent, market-beating returns, supported by a robust growth portfolio and prudent capital allocation. AMGN's pipeline strength is evident, with 16 drugs on track for blockbuster status and promising new assets like MariTide in obesity. At a forward P/E of 15.1 and 3% yield, AMGN offers an attractive blend of income and growth, justifying a continued ‘Buy' rating.
On May 26, 2026, we delve into the discounted cash flow (DCF) analysis for Amgen Inc (AMGN), a biopharmaceutical company that has shown a solid price performanc
The Japanese drugmaker that sells rare-disease medicine Tavneos said new patients will be able to get the drug, which carries risk of liver injury.
Amgen said on Tuesday its chief financial officer, Peter Griffith, would retire, with Thomas Dittrich taking over the role in September.
Thomas Dittrich Returning to Amgen as CFO THOUSAND OAKS, Calif., May 19, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the retirement of Peter Griffith, who has served as the company's executive vice president and chief financial officer since 2020.
At least 20 people in Japan who took Amgen's rare disease drug have died, while 22 others developed potentially fatal liver injuries, the Wall Street Journal reported on Friday, citing partner Kissei Pharmaceutical.
Kissei Pharmaceutical, which sells the rare immune-disease drug in Japan, warned doctors to stop prescribing it to new patients.
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Amgen Inc. (AMGN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
On a recent episode of The Compound and Friends, hosts Josh Brown and Michael Batnick sat down with former Janus analyst Matt Ancrum to discuss his study of 100-bagger stocks.
On May 11, 2026, we delve into the discounted cash flow (DCF) analysis for Amgen Inc (AMGN), a company that has shown a price performance of +25.8% over the pas
Amgen is handling a recent patent cliff pretty well. Merck is well prepared for its own upcoming patent cliff.
THOUSAND OAKS, Calif., May 7, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 10:00 a.m.
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Royalty Pharma (RPRX) and Amgen (AMGN). But which of these two stocks presents investors with the better value opportunity right now?
Guggenheim trimmed its price target (PT) on Amgen (NASDAQ:AMGN | AMGN Price Prediction) to $340 from $351 on Monday, May 4, while maintaining a Neutral rating.
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Amgen said on Monday it was investing an additional $300 million in Puerto Rico to expand its U.S. manufacturing network.
Investment Strengthens American Manufacturing, Supply Chain Resilience and Next-Generation Technology THOUSAND OAKS, Calif., May 4, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced plans to invest an additional $300 million in its U.S. manufacturing network to further advance U.S.-based production capacity, enhance next-generation technologies and support a reliable supply of medicines for patients.
On May 04, 2026, we present a DCF analysis for Amgen Inc (AMGN), a biopharmaceutical company known for its innovative therapies. The stock has experienced some
AMGN beats Q1 estimates as 16 drugs post double-digit growth, offsetting biosimilar erosion and weaker legacy products while lifting 2026 outlook.
Amgen Inc. (AMGN) Q1 2026 Earnings Call Transcript
Revenue: Total revenues expected in the range of $37.1 billion to $38.5 billion for 2026.Product Sales Growth: 4% growth in product sales in Q1 2026.Key Growth
While the top- and bottom-line numbers for Amgen (AMGN) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Amgen (AMGN) came out with quarterly earnings of $5.15 per share, beating the Zacks Consensus Estimate of $4.73 per share. This compares to earnings of $4.9 per share a year ago.
The biotechnology company reported a profit of $1.82 billion, driven by a 4% rise in product sales.
Amgen on Thursday reported first-quarter product sales rose 4%, helped by demand for cholesterol and rare disease medicines, and said it was moving forward with a broad development program for experimental weight-loss drug MariTide.
THOUSAND OAKS, Calif., April 30, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2026.
Amgen heads into Q1 earnings with growth from key drugs offset by pricing pressure, patent losses, and biosimilar competition.
The iShares Biotechnology ETF (IBB) was launched on 02/05/2001, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.
The U.S. Food and Drug Administration's Center for Drug Evaluation and Research on Monday proposed withdrawing approval of Amgen's drug for a group of rare autoimmune diseases, citing a lack of proven effectiveness and untrue statements in the application that led to its approval.
Novartis, Amgen and Eli Lilly are among the pharmaceutical companies developing drugs to lower levels of a particularly bad form of cholesterol called Lp(a) and potentially prevent heart attacks. Lp(a) levels are almost entirely genetically determined, making them a prime target for drugmakers.
Evaluate the expected performance of Amgen (AMGN) for the quarter ended March 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Company Showcases SteraMist iHP Automation to Industry Giants Including Amgen, Merck, and Moderna; Finalizes Custom Engineering Contract for Proprietary Healthcare System Company Showcases SteraMist iHP Automation to Industry Giants Including Amgen, Merck, and Moderna; Finalizes Custom Engineering Contract for Proprietary Healthcare System
On April 27, 2026, we present a detailed DCF analysis for Amgen Inc (AMGN), a company that has shown a price performance of +27.0% over the past year, despite a
Comerica Bank lowered its stake in shares of Amgen Inc. (NASDAQ: AMGN) by 6.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 155,074 shares of the medical research company's stock after selling 10,395 shares during the period. Comerica Bank's holdings in
Amgen (AMGN) closed the most recent trading day at $344.55, moving 1.17% from the previous trading session.
THOUSAND OAKS, Calif., April 24, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2026 financial results on Thursday, April 30, 2026, after the close of the U.S. financial markets.
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amgen (NASDAQ: AMGN - Get Free Report) will likely be posting its Q1 2026 results after the market closes on Thursday, April 30th. Analysts expect Amgen to post earnings of $4.74 per share and revenue of $8.5772 billion for the quarter. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Investors may review the information
Boston Trust Walden Corp grew its holdings in Amgen Inc. (NASDAQ: AMGN) by 390.1% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 71,905 shares of the medical research company's stock after buying an additional 57,235 shares during the quarter. Boston
Organizational Changes Further Emphasize Integration of Biology and Technology THOUSAND OAKS, Calif., April 22, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the retirement of David M.
Viridian Therapeutics is a clinical-stage biotech awaiting an FDA decision on its lead thyroid eye disease therapy.
